Research in Social and Administrative Pharmacy
Volume 1, Issue 2 , Pages 251-269 , June 2005

Drug information–seeking intention and behavior after exposure to direct-to-consumer advertisement of prescription drugs

  • Yifei Liu, M.S.

      Affiliations

    • Pharmaceutical Socioeconomics, S-532 PHAR, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 319 335 7960; fax: +1 319 353 5646.
    • ,
  • William R. Doucette, Ph.D.

      Affiliations

    • Pharmaceutical Socioeconomics, S-532 PHAR, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
    • ,
  • Karen B. Farris, Ph.D.

      Affiliations

    • Pharmaceutical Socioeconomics, S-532 PHAR, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
    • ,
  • Dhananjay Nayakankuppam, Ph.D.

      Affiliations

    • Department of Marketing, Henry B. Tippie College of Business, University of Iowa, Iowa City, IA 52242, USA

References 

  1. Yuan Y, Duckwitz N. Doctors and DTC. <http://www.imshealth.com>August, 2002;Accessed 02.19.03
  2. United States General Accounting Office. FDA oversight of direct-to-consumer advertising has limitations. Report to congressional requesters. Report no. GAO-03-177. October 2000.
  3. Miller B. Are current DTC ads ineffective?. Med Mark Media. 1999;34:38–47
  4. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff. 2003;W3-82–W3-95
  5. Melillo W. FDA cites most DTC drug spots. Adweek. 1999;40:4
  6. Free rein for drug ads? A slowdown in FDA review has left consumers more vulnerable to misleading messages. Consum Rep. 2003;68:33–37
  7. Moncavage M. US FDA, Division of Drug Marketing, Advertising and Communications. DTC prescription drug promotion update from FDA. Presented at DTC National 2003. Boston, Mass. March, 2003. <www.fda.gov/cder/ddmac/presentations.htm>. Accessed 04.20.03.
  8. Aikin JK. US FDA, Division of Drug Marketing, Advertising and Communications. Direct-to-consumer advertising of prescription drugs: patient survey results. Presented at Healthcare Marketing Communications Council. September, 2002. <www.fda.gov/cder/ddmac/presentations.htm>. Accessed 01.20.03.
  9. Maddux JE, Brawley L, Boykin A. Self-efficacy and health behavior: prevention, promotion and detection. [chapter 6] In:  Maddux JE editors. Self-efficacy, Adaptation, and Adjustment: Theory, Research, and Application. New York, NY: Plenum Press; 1995;p. 19–27
  10. Ajzen I. Attitudes, Personality, and Behavior. Chicago, Ill: Dorsey Press; 1988;
  11. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211
  12. Roter DL. Patient question asking in physician-patient interaction. Health Psychol. 1984;3:395–409
  13. Schommer JC, Wiederholt JB. Pharmacists' perceptions of patients' needs for counseling. Am J Hosp Pharm. 1994;51:478–485
  14. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977;84:191–215
  15. Bandura A. Self-efficacy mechanism in human agency. Am Psychol. 1982;37:122–147
  16. Bandura A. Social Foundations of Thought and Action: a Social Cognitive Theory. Englewood Cliffs, NJ: Prentice-Hall; 1986;
  17. Bandura A. Health promotion from the perspective of social cognitive theory. Psychol Health. 1998;13:623–649
  18. Ajzen I, Madden TJ. Prediction of goal-directed behavior: attitudes, intentions, and perceived behavioral control. J Exp Soc Psychol. 1986;22:453–474
  19. Trafimow D, Sheeran P, Conner M, Finlay KA. Evidence that perceived behavioral control is a multidimensional construct: perceived control and perceived difficulty. Br J Soc Psychol. 2002;41:101–121
  20. Azjen I. Perceived behavioral control, self-efficacy, locus of control, and the theory of planned behavior. J Appl Soc Psychol. 2002;32:1–20
  21. Armitage CJ, Conner M. Social cognitive determinants of blood donation. J Appl Soc Psychol. 2001;31:1431–1457
  22. Armitage CJ, Conner M. Distinguishing perceptions of control from self-efficacy: predicting consumption of a low-fat diet using the theory of planned behavior. J Appl Soc Psychol. 1999;29:72–90
  23. Armitage CJ, Conner M. The theory of planned behaviour: assessment of predictive validity and “perceived control”. Br J Soc Psychol. 1999;38:35–54
  24. Manstead ASR, van Eekelen SAM. Distinguishing between perceived behavioral control and self-efficacy in the domain of academic intentions and behaviors. J Appl Soc Psychol. 1998;28:1375–1392
  25. Povey R, Conner M, Sparks P, James R, Shepherd R. Application of the theory of planned behaviour to two dietary behaviours: roles of perceived control and self-efficacy. Br J Health Psychol. 2000;5:121–139
  26. Terry DJ, O'Leary JE. The theory of planned behaviour: the effects of perceived behavioural control and self-efficacy. Br J Soc Psychol. 1995;34:199–220
  27. Sparks P, Guthrie CA, Shepherd R. The dimensional structure of the perceived behavioral control construct. J Appl Soc Psychol. 1997;27:418–438
  28. Odeina FT, Helper CD, Segal R, Miller D. The pharmacist's implementation of pharmaceutical care (PIPC) model. Pharm Res. 1997;14:135–144
  29. Farris KB, Schopflocher DP. Between intention and behavior: an application of community pharmacists' assessment of pharmaceutical care. Soc Sci Med. 1999;49:55–66
  30. Cheung SF, Chan DKS. The Role of Perceived Behavioral Control in Predicting Human Behavior: a Meta-analytic Review of Studies on the Theory of Planned Behavior. Chinese University of Hong Kong; 2000, unpublished manuscript.
  31. Conner M, Armitage CJ. Extending the theory of planned behavior: a review and avenues for future research. J Appl Soc Psychol. 1998;28:1429–1464
  32. Netemeyer RG, Burton S, Johnson M. A comparison of two models for the prediction of volitional and goal-directed behaviors: a confirmatory analysis approach. Soc Psychol Q. 1991;54:87–100
  33. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–514
  34. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990;33:1601–1610
  35. Felson DT, Lawrence RC, Diepe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635–646
  36. Levy PS, Lemeshow S. How large a sample do we need? Simple random sampling. [chapter 3] In:  Levy PS,  Lemeshow S editor. Sampling of Population: Methods and Application. 3rd ed.. New York, NY: John Wiley & Sons; 1999;p. 70–75
  37. Dillman DA. Mail and Internet Surveys: the Tailored Design Method. 2nd ed.. New York, NY: John Wiley Co; 1999;
  38. Aikin JK, Swasy J. US FDA, Division of Drug Marketing, Advertising and Communications. Analysis of the effects of DTC advertising on patient information seeking behavior. Presented at Drug Information Association. July, 2001. <www.fda.gov/cder/ddmac/presentations.htm>. Accessed 01.20.03.
  39. Bellamy N, Watson Buchanan W, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or the knee. J Rheumatol. 1988;15:1833–1840
  40. Prevention Magazine and APhA. “Navigating the medical marketplace: how consumers choose,” a joint survey. Washington, DC. 1997.
  41. Doucette WR, Schommer JC. Consumer preferences for drug information after direct-to-consumer advertising. Drug Inf J. 1998;32:1081–1088
  42. Peat G, Croft P, Hay E. Clinical assessment of the osteoarthritis patient. Best Pract Res Clin Rheumatol. 2001;15:527–544
  43. Sutton S. Predicting and explaining intentions and behavior: how well are we doing?. J Appl Soc Psychol. 1998;28:1317–1338
  44. Siebert DC, Mutran EJ, Reitzes DC. Friendship and social support: the importance of role identity to aging adults. Soc Work. 1999;44:522–533
  45. Peterson MW, Fretz PC. Patient use of the internet for information in a lung cancer clinic. Chest. 2003;123:452–457
  46. Fishbein M, Ajzen I. Belief, Attitude, Intention, and Behavior: an Introduction to Theory and Research. Reading, Mass: Addison-Wesley; 1975;
  47. Three out of four Americans have access to the Internet, according to Nielsen Netratings. New York, NY: Netratings Inc; 2004.
  48. Cotton SR, Gupta SS. Characteristics of online and offline health information seekers and factors that discriminate between them. Soc Sci Med. 2004;59:1795–1806
  49. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med. 1999;14:651–657
  50. Foley L, Gross DJ. Are Consumers Well Informed About Prescription Drugs? The Impact of Printed Direct-to-consumer Advertising. Washington, DC: AARP Public Policy Institute; 2000;
  51. FDA. Warning letter to Merck & Co Inc NDA 21-042 MACMIS ID # 9456 Vioxx (rofecoxib) tablets. Rockville, Md: FDA; 2001.
  52. FDA. Letter to G.D. Searle & Co re NDA 20-998 Celebrex (celecoxib) capsules, NDA 19-908 Ambien (zolpidem tartrate) tablets MACMIS ID #8518. Department of Health & Human Services; 2000.
  53. FDA. Letter to G.D. Searle & Co re NDA 20-998 Celebrex (celecoxib) capsules MACMIS ID #9514. Department of Health & Human Services; 2000.
  54. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528
  55. Peck P. Merck issues worldwide recall of Vioxx®. New York, NY: United Press International; 2004.
  56. Pfizer pulling ads for Celebrex®. CNN news. New York, NY. December 20, 2004. <http://money.cnn.com/2004/12/20/news/celebrex/index.htm>. Accessed 12.21.04.

PII: S1551-7411(05)00042-2

doi: 10.1016/j.sapharm.2005.03.010

Research in Social and Administrative Pharmacy
Volume 1, Issue 2 , Pages 251-269 , June 2005

Article Tools

* Image Usage & Resolution